BioMedBC Project

BioMedBC Project is focused on improving the patient management of Bladder Cancer

 

Epidemiology and Treatment

Bladder Cancer (BC) is the 4th most common cancer in men and the 11th most common in women [1].

It is characterized by the highest recurrence rate and it is the costliest cancer type to manage. The majority of BC (~70%) are

classified as Non Muscle Invasive (NMIBC, stages Ta,T1, Tis) and are treated by transurethral resection and BCG intravesical

immunotherapy [2]; whereas ~30% are Muscle Invasive (MIBC, stages T2-4) and treated by radical cystectomy, (neo)adjuvant

chemotherapy or (chemo)radiotherapy [3-5]. Still, ~40% of the NMIBC patients do not fully respond to BCG treatment. As the current

therapeutic options are limited, MIBC patients also present with poor 5-year survival rate (30-50%) [6]. Apart from cisplatin-based

chemotherapy and cystectomy, no other treatment has been established for the past 30 years, with the exception of a recently

introduced immunotherapy that targets the PD-L1 molecule. Phenotypic diversity in urological tumors is delaying the translation of

the clinical trials’ results to new standard treatment options.

 

 

 

Clinical Challenges

Unraveling the molecular alterations in the incipient phases of BC is important for the establishment of earlier

therapeutic interventions. While reliable biomarkers (BM) for patient stratification are currently not available for clinical use, the

newly designed clinical trials, highlight the value of companion tests, i.e. prognostic and predictive BM, to guide intervention.

Therefore, the identification of BC molecular signatures to enable the stratification of BC patients is a challenge culminating in the

vision of personalized therapy that will significantly improve on patient management. Using cutting-edge clinical proteomics

platforms, the BioMedBC proposal focuses on the application of systems biology and cross-omics data integration methodologies to

achieve:

a) the molecular characterization of BC and

b) develop signatures to predict the clinical outcome

 

 

 

References

  1. Kamat, A.M., et al., Bladder cancer. Lancet, 2016.
  2. Babjuk, M., et al., EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol, 2013. 64(4): p. 639-53.
  3. Kaufman, D.S., W.U. Shipley, and A.S. Feldman, Bladder cancer. Lancet, 2009. 374(9685): p. 239-49.
  4. Witjes, J.A., et al., EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol, 2014. 65(4): p. 778-92.
  5. Prasad, S.M., et al., Urothelial carcinoma of the bladder: definition, treatment and future efforts. Nat Rev Urol, 2011. 8(11): p. 631-42.
  6. Kiselyov, A., S. Bunimovich-Mendrazitsky, and V. Startsev, Key signaling pathways in the muscle-invasive bladder carcinoma: Clinical markers for disease modeling and optimized treatment. Int J Cancer, 2016. 138(11): p. 2562-9.

 

 
 
 
BioMedBC is a Marie Sklodowska Curie Actions (MSCA) Individual Fellowship programme (H2020-MSCA-IF-2016)
funded by the European Union under the Horizon2020 Framework Programme (Grant Agreement:752755) and
coordinated by Mosaiques diagnostics